Evidence map›Paper›PMID 40038735›Full record

ArticleMalaria journal2025

In vitro and in silico evaluation of synthetic compounds derived from bi-triazoles against asexual and sexual forms of Plasmodium falciparum.

Leandro do Nascimento Martinez, Minelly Azevedo da Silva, Saara Neri Fialho, Marcinete Latorre Almeida, Amália Dos Santos Ferreira, Aurileya de Jesus Gouveia, Welington da Silva Paula do Nascimento, Ana Paula de Azevedo Dos Santos, Norton Rubens Diunior Lucas Pejara Rossi, Jansen Fernandes de Medeiros and 6 more

Abstract read
In one paragraph

Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Leandro do Nascimento MartinezPlataforma de Bioensaios de Malária E Leishmaniose (PBML), Fundação Oswaldo Cruz, FIOCRUZ, Unidade Rondônia, Porto Velho, RO, Brazil. leandro.martinez@fiocruz.br.
Minelly Azevedo da SilvaInstituto Federal de Educação, Ciência e Tecnologia de Rondônia - IFRO, Porto Velho, Brazil.
Saara Neri FialhoPlataforma de Bioensaios de Malária E Leishmaniose (PBML), Fundação Oswaldo Cruz, FIOCRUZ, Unidade Rondônia, Porto Velho, RO, Brazil.
Marcinete Latorre AlmeidaPlataforma de Bioensaios de Malária E Leishmaniose (PBML), Fundação Oswaldo Cruz, FIOCRUZ, Unidade Rondônia, Porto Velho, RO, Brazil.
Amália Dos Santos FerreiraPlataforma de Bioensaios de Malária E Leishmaniose (PBML), Fundação Oswaldo Cruz, FIOCRUZ, Unidade Rondônia, Porto Velho, RO, Brazil.
Aurileya de Jesus GouveiaPlataforma de Bioensaios de Malária E Leishmaniose (PBML), Fundação Oswaldo Cruz, FIOCRUZ, Unidade Rondônia, Porto Velho, RO, Brazil.
Welington da Silva Paula do NascimentoPlataforma de Bioensaios de Malária E Leishmaniose (PBML), Fundação Oswaldo Cruz, FIOCRUZ, Unidade Rondônia, Porto Velho, RO, Brazil.
Ana Paula de Azevedo Dos SantosCentro Universitário São Lucas -PVH/Afya, Porto Velho, RO, Brazil.
Norton Rubens Diunior Lucas Pejara RossiPlataforma de Bioensaios de Malária E Leishmaniose (PBML), Fundação Oswaldo Cruz, FIOCRUZ, Unidade Rondônia, Porto Velho, RO, Brazil.
Jansen Fernandes de MedeirosPrograma de Pós-Graduação Em Biologia Experimental (PGBIOEXP), Fundação Universidade Federal de Rondônia (UNIR), Porto Velho, RO, Brazil.
Natalie Ferreira AraújoLaSOPB - Laboratório de Síntese Orgânica e Prospecção Biológica, InstitutodeQuímica, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, RJ, 21941-909, Brazil.
Quelli Larissa Oliveira de SantanaLaSOPB - Laboratório de Síntese Orgânica e Prospecção Biológica, InstitutodeQuímica, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, RJ, 21941-909, Brazil.
Carlos Roland KaiserLaSOPB - Laboratório de Síntese Orgânica e Prospecção Biológica, InstitutodeQuímica, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, RJ, 21941-909, Brazil.
Sabrina Baptista FerreiraLaSOPB - Laboratório de Síntese Orgânica e Prospecção Biológica, InstitutodeQuímica, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, RJ, 21941-909, Brazil.
Maisa da Silva AraujoPrograma de Pós-Graduação em Biodiversidade e Biotecnologia da Amazônia Legal - BIONORTE, Porto Velho, RO, Brazil.
Carolina Bioni Garcia TelesPlataforma de Bioensaios de Malária E Leishmaniose (PBML), Fundação Oswaldo Cruz, FIOCRUZ, Unidade Rondônia, Porto Velho, RO, Brazil.

Funding

Gates Foundation INV-003970
6 · The paper itself

Abstract

backgroundDespite advances in malaria chemotherapy, the disease continues to claim thousands of lives annually. Addressing this issue requires the discovery of new compounds to counteract resistance threatening the current therapeutic arsenal. In this context, bi-triazoles are substances with diverse biological activities, showing promise as lead compound to fight malaria. Triazoles are heterocyclic structures composed of five members, including three nitrogen atoms and two double bonds. Bi-triazoles, the focus of this study, are derivatives of triazoles consisting of two triazole rings (nitrogen heterocyclic) with isolated nuclei lacking a spacer and two substituents at each end. The goal of the present study was to assess the in vitro and in silico, antimalarial activity of bi-triazole compounds 14c, 14d, 13c, and 13d against asexual and sexual forms of Plasmodium falciparum.

methodsFor in silico predictions, the software OSIRIS, Molinspiration, and ADMETlab were employed. To determine the 50% inhibitory concentration (IC

resultsIn silico analyses of physicochemical properties revealed that all compounds have favorable potential for drug development. Pharmacokinetics predictions also provided important, novel insights into this chemical class. Antimalarial activity tests showed that compounds 14d and 13d exhibited promising activity, with IC

conclusionOverall, the in vitro and in silico results showed that bi-triazole compounds may guide new biological investigation for malaria, enabling the identification and development of more active and selective antimalarial agents.

Indexed as

AntimalarialsPlasmodium falciparumTriazolesComputer SimulationHumansInhibitory Concentration 50AntimalarialsTriazolesBi-triazolesGametocytesIn silicoPlasmodium falciparumTransmission blocking

Identifiers

PMID40038735
PMCPMC11881275

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.